

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**康臣葯業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1681)**

## **POSITIVE PROFIT ALERT**

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six-month period ended 30 June 2017, it is expected that the Group would record a significant increase in profit attributable to equity shareholders of the Company for the six-month period ended 30 June 2017 as compared with that for the six-month period ended 30 June 2016, which was mainly attributable to the increases in sales of Uremic Clearance Granules and women and children products and the consolidation of the operating results of Guangxi Yulin Pharmaceutical Group Limited during the period.

The information set out in this announcement is only based on the information currently available to the Company and the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the six-month period ended 30 June 2017, which is subject to finalization and other potential adjustments (if necessary), and has not been audited or reviewed by the Company’s auditor or the audit committee of the Board. Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the six-month period ended 30 June 2017, which is expected to be published on 24 August 2017.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Yubao**  
*Chairman*

Hong Kong, 24 July 2017

*As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. LIN Sheng as non-executive Director; Mr. SU Yuan fu, Mr. FENG Zhong shi and Ms. CHENG Xinxin as independent non-executive Directors.*